Search the Newsreel

Webster Financial Corporation (WBS) Stock Forecasts

Argus has raised its target price for Webster Financial Corporation (WBS) to $87.00. Webster Financial Corp is a full-service financial services provider offering commercial and consumer banking, mortgages, and investment advisory services across several Northeastern states. The current price for WBS is $78.78.

Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts

Emergent BioSolutions laying off dozens, shedding real estate as Narcan competition strains profits

Emergent BioSolutions is undergoing significant restructuring, including layoffs and real estate divestment, to cut costs. These measures are a response to increased competition for its key product, Narcan, an over-the-counter opioid overdose reversal spray. The company has been implementing these changes since Joe Papa …

Emergent BioSolutions | 10-Q: Q2 2026 Earnings Report

This article provides the Q2 2026 earnings report for Emergent BioSolutions. It is a quarterly filing (10-Q) that details the company's financial performance during the second quarter of 2026.

Emergent BioSolutions Inc. 2026: Revenue $234.3M, EPS ($3.49) — 10-Q Summary

Emergent BioSolutions Inc. reported its second-quarter 2026 results, with revenue increasing to $234.3M from $140.9M year-over-year. Despite this growth, the company recorded a net loss of ($180.2M) and diluted EPS of ($3.49), primarily due to a $191M non-cash impairment on NARCAN® intangible assets. The …

Krebs Biochemicals & Industries reports standalone net loss of Rs 2.48 crore in the June 2026 quarter

Krebs Biochemicals narrows Q1FY26 net loss 53% on revenue surge

Krebs Biochemicals Q1 Results: Net loss narrows to ₹248 lakh as revenue rises

Emergent BioSolutions (NYSE: EBS) posts Q2 loss, plans cost-cutting

Is Emergent BioSolutions Inc (EBS) Overvalued After Q2 Earnings

Emergent BioSolutions Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:EBS) 2026-08-05

Key Points Interested in Emergent Biosolutions Inc.? Here are five stocks we like better. Q2 performance exceeded expectations: Revenue reached $234 million and adjusted EBITDA rose to $97 million, driven by accelerated medical countermeasure deliveries and strong U.S. government contract activity. NARCAN competition is …

Emergent BioSolutions Reports Second Quarter 2026 Financial Results

Emergent BioSolutions announced its second-quarter 2026 financial results, reporting total revenues of $234.3 million, a 66% increase year-over-year, and an adjusted net income of $30.9 million, up 134%. Despite a significant net loss due to a non-cash impairment charge, the company is implementing a …

Emergent records $191.3M non-cash charge related to NARCAN asset group

Emergent BioSolutions reported Q2 2026 total revenues of $234.3 million, a 66% increase year-over-year, driven primarily by higher U.S. government sales of smallpox and other medical countermeasure products. Despite this revenue growth and improved adjusted net income and EBITDA, the company posted a GAAP …

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

Emergent BioSolutions (NYSE: EBS) emphasizes the critical need for cross-sector collaboration to address evolving biological threats stemming from geopolitical conflicts, AI, and synthetic biology. The company highlights calls from European health officials and AI industry leaders for stronger safeguards and points to recent anthrax-related …

Websol Energy System to host Q1FY27 earnings call on Aug 11 at 4 PM

Earnings call transcript: Emergent BioSolutions Q2 2026 revenue tops guidance

This article provides the Q2 2026 earnings report for Emergent BioSolutions. It is a quarterly filing (10-Q) that details the company's financial performance during the second quarter of 2026.

Emergent Biosolutions (NYSE:EBS) Announces Quarterly Earnings Results

Webster Financial Corp stock hits all-time high at 77.7 USD

Webster Financial Corp's stock has reached an all-time high of $77.69, reflecting a 41.38% 1-year return and highlighting strong investor confidence, despite an InvestingPro analysis suggesting it might be slightly overvalued. The company has a 40-year record of dividend payments. This milestone comes as …

Emergent BioSolutions Inc expected to post earnings of 11 cents a share - Earnings Preview

Emergent BioSolutions Inc. (EBS) is expected to announce earnings of 11 cents per share. This information comes from a Refinitiv earnings preview. The full article is available through TradingView News, which offers access to Reuters and other news sources.

Webster Financial Corporation $WBS Shares Acquired by California State Teachers Retirement System

Will Steady Earnings, Higher Charge-Offs and Buybacks Change Webster Financial's (WBS) Capital Return Narrative

Vanguard Capital Management (EBS) discloses 4.92% Emergent BioSolutions ownership

Vanguard Capital Management LLC and its affiliates have reported a beneficial ownership of 2,540,945 shares of Emergent BioSolutions Inc. common stock, which constitutes 4.92% of the total class as of June 30, 2026. This Schedule 13G/A filing indicates that Vanguard has sole voting power …

EBS|Emergent BioSolutions Inc|Price:7.220|Chg%:-0.050

This article provides a comprehensive stock analysis of Emergent BioSolutions Inc (EBS) by TradingKey, assigning it a "fairly valued" rating and a score of 6.62/10 in the Pharmaceuticals industry. The analysis highlights healthy fundamentals, high growth potential, and strong institutional ownership, despite a recent …

Webster Financial (WBS) Reports Steady Q2 Results And Dividends, Is It Now 4% Overvalued?

Press Release: Webster Financial Corporation Declares Common and Preferred Dividends

Webster Financial Corporation (NYSE: WBS) announced that its Board of Directors has declared a quarterly cash dividend of $0.40 per share on its common stock, payable on August 21, 2024, to shareholders of record as of August 7, 2024. The board also declared quarterly …

Emergent BioSolutions Inc (EBS) Institutional Confidence

Emergent BioSolutions Inc (EBS) has an institutional shareholding score of 7.00, placing it 50th out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 81.98%, a slight decrease quarter-over-quarter. James Simons is the largest institutional shareholder, with other significant holders including BlackRock …

Emergent Biosolutions (EBS) Projected to Post Earnings on Wednesday

Temple & Webster (ASX:TPW): Can Revenue Growth Support a Broader Earnings Recovery?

Emergent BioSolutions Inc (EBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Emergent BioSolutions Inc (EBS), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It shows that EBS has a price momentum score of 3.62, trading between a resistance of 8.22 and support …

Emergent BioSolutions | SCHEDULE 13G/A: Others

This article is a SCHEDULE 13G/A filing related to Emergent BioSolutions. It indicates an amendment to a previous filing, typically involving changes in beneficial ownership of the company's stock by a significant investor.

Emergent BioSolutions Inc (EBS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Emergent BioSolutions Inc (EBS), noting its current valuation score of 9.29 and ranking within the Pharmaceuticals industry. It highlights the company's P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet …

Emergent BioSolutions Inc (EBS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Emergent BioSolutions Inc (EBS), outlining its major institutional holders, investor types, and activity. It highlights that BlackRock, Dimensional Fund Advisors, and State Street are among the top shareholders. The report also provides a historical overview of institutional …

Whitebox Advisors LLC Purchases Shares of 1,925,001 Webster Financial Corporation $WBS

EBS|Emergent BioSolutions Inc|Price:7.260|Chg%:-0.240

This article provides an overview of Emergent BioSolutions Inc. (EBS), a life sciences company focusing on public health threats with products like NARCAN Nasal Spray and various contract manufacturing services. It details key company information, financial data, and lists executive leadership along with their …

EBS5025997 Bond Risk Profile

This article provides a risk profile for the Emergent BioSolutions Inc. 3.875% 15-AUG-2028 bond, identified as EBS5025997. It offers an overview of the bond's coupon, redemption, and risks, including a credit risk assessment with key metrics. The information is designed to help users evaluate …

EBS5025997 Bond Profile — Key Metrics

This article provides key metrics for the EBS5025997 bond issued by Emergent BioSolutions Inc. It details the bond's coupon rate, maturity date, outstanding amount, and face value, alongside a company profile. The bond is a 3.875% bond maturing on August 15, 2028.